Viewing Study NCT00433095


Ignite Creation Date: 2025-12-24 @ 1:36 PM
Ignite Modification Date: 2026-02-12 @ 3:40 AM
Study NCT ID: NCT00433095
Status: COMPLETED
Last Update Posted: 2011-03-14
First Post: 2007-02-07
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
Sponsor: Ludwig-Maximilians - University of Munich
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma Breast Stage IV View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Navelbine View
None Herceptin View
None oral View
None breast cancer View